Resverlogix Corp
- LAST PRICE0.0650
- TODAY'S CHANGE (%)0.0100 (18.1818%)
- Bid / Lots0.0600/ 7
- Ask / Lots0.0650/ 92
- Open / Previous Close0.0600 / 0.0550
- Day Range
- 52 Week Range
- Volume67,900
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RVX |
|---|---|---|
| 09:50 ET | 10000 | 0.06 |
| 11:25 ET | 49000 | 0.065 |
| 01:02 ET | 1000 | 0.065 |
| 03:51 ET | 7000 | 0.065 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Resverlogix Corp | 15.3M | -1.1x | --- |
BioMark Diagnostics Inc | 21.4M | -12.3x | --- |
Biovaxys Technology Corp | 18.3M | -2.4x | --- |
Quantum BioPharma Ltd | 12.6M | -0.4x | --- |
Sirona Biochem Corp | 17.0M | -6.2x | --- |
BetterLife Pharma Inc | 16.2M | -2.7x | --- |
Company Information
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
Contact Information
- Headquarters
- 300-4820 Richard Rd SWCALGARY, AB, Canada T3E 6L1
- Phone
- 403-254-9252
- Fax
- 403-254-9252
Executives
- Chairman of the Board, President, Chief Executive Officer, Secretary
- Donald Mccaffrey
- Chief Financial Officer
- A. Brad Cann
- Senior Vice President - Clinical Development
- Michael Sweeney
- Chief Scientific Officer
- Ewelina Kulikowski
- Lead Independent Director
- Kelly Mcneill
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 278.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.79 |
EPS | $-0.06 |
Book Value | $-0.38 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
